Abstract
Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have